View Older Stories View More Recent Stories

Jun 4, 2018 07:36AM Merck (MRK) Highlights Long-Term Survival Benefit in KEYTRUDA® (pembrolizumab)
Jun 4, 2018 07:30AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Long-Term Survival Benefit Based on Four and Five Years of Follow-Up from Two Pivotal Studies in Advanced Melanoma
Jun 4, 2018 06:22AM Merck (MRK) & Eisai Highlights New Data and Analyses of LENVIMA (lenvatinib) in Combination with Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab)
Jun 4, 2018 06:17AM Merck's (MRK) KEYTRUDA Plus Chemo Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous NSCLC
Jun 3, 2018 06:00PM Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types
Jun 3, 2018 09:00AM Merck’s KEYTRUDA® (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC) in Phase 2 KEYNOTE-427 Stud
Jun 3, 2018 07:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Phase 3 KEYNOTE-407 Study
Jun 3, 2018 07:30AM KEYTRUDA® (pembrolizumab) Monotherapy Significantly Improved Overall Survival in KEYNOTE-042 Study as First-Line Treatment for Locally Advanced or Metastatic NSCLC Patients Whose Tumors Expressed PD-
Jun 1, 2018 08:06AM Advaxis (ADXS) Announced Prelim. Data from Ongoing Metastatic, Castration Resistant Prostate Cancer (mCRPC) Phase 1/2 KEYNOTE-046 Study, Conducted in Conjunction with Merck (MRK) Evaluating ADXS-PSA
May 31, 2018 08:53AM Merck and Premier Inc. Collaborating to Help Reduce Clostridium difficile (C. diff) Infection
May 24, 2018 07:34PM Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma
May 24, 2018 07:05AM Foundation Medicine (FMI) Reports Immuno-Oncology Companion Diagnostics Collaboration with Merck (MRK)
May 23, 2018 06:46AM Merck's (MRK) KEYTRUDA Significantly Improved OS and PFS as First-Line Treatment for NSCLC in Pivotal Phase 3 KEYNOTE-407 Trial
May 23, 2018 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KE
May 22, 2018 02:21PM Merck Announces Third-Quarter 2018 Dividend
May 16, 2018 05:05PM New Data from Merck’s Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting
May 8, 2018 06:50AM AstraZeneca (AZN), Merck (MRK) LYNPARZA Tablets Receive EU Approval for Treatment of Platinum-Sensitive Relapsed Ovarian Cancer
May 8, 2018 06:45AM LYNPARZA® (olaparib) Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer
May 7, 2018 07:03AM Veeva Announces Merck’s Expanded Use of Veeva CRM for Latin America and Asia Pacific
May 3, 2018 04:55PM Moderna and Merck (MRK) Expand mRNA Cancer Vaccines Pact
May 3, 2018 04:15PM Moderna and Merck Expand mRNA Cancer Vaccines Collaboration
May 3, 2018 06:46AM Merck (MRK) KEYNOTE-407 Trial Met Pre-specified Secondary Endpoint
May 3, 2018 06:45AM Merck Provides Update on KEYNOTE-407 Trial
May 1, 2018 06:45AM Merck Announces First-Quarter 2018 Financial Results
Apr 30, 2018 06:46AM Merck (MRK) Announces FDA Granted Priority Review to its sBLA for KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Treatment of Metastatic Nonsquamous NSCLC
Apr 30, 2018 06:45AM FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy Based on Results from Phase 3 KEYNOTE-189 Trial as Firs
Apr 23, 2018 04:35PM Merck (MRK) Reports EMA Validation of Type II Variation for KEYTRUDA (pembrolizumab) in Combination with Pemetrexed (ALIMTA) and Platinum Chemotherapy
Apr 23, 2018 04:30PM European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic N
Apr 17, 2018 08:35AM Merck (MRK) Says It's Beginning Two Phase 3 Studies of PCV-15 (V114), Its Investigational Pneumococcal Disease Vaccine
Apr 17, 2018 08:30AM Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine
Apr 16, 2018 09:35AM Merck (MRK) Announces Results from KEYNOTE-189, a Pivotal Phase 3 Trial Evaluating KEYTRUDA (anti-PD-1 therapy) in Combination with Pemetrexed (ALIMTA) and Cisplatin
Apr 16, 2018 09:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsqu
Apr 16, 2018 05:58AM AstraZeneca (AZN) & Merck (MRK) Report Overall Survival Data for LYNPARZA (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer
Apr 16, 2018 05:52AM Merck (MRK) Reports Results from Phase 3 EORTC1325/KEYNOTE-054 Trial Investigating KEYTRUDA as Adjuvant Therapy
Apr 15, 2018 04:50PM Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR
Apr 15, 2018 09:30AM Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma
Apr 9, 2018 06:45AM Merck (MRK) Says KEYTRUDA Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study
Apr 9, 2018 06:45AM KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing P
Apr 6, 2018 07:32AM Incyte (INCY) Phase 3 ECHO-301 Study Didn't Meet Primary Endpoint
Apr 6, 2018 07:30AM Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma
Apr 3, 2018 06:02AM Merck (MRK) Reports EMA Acceptance of Regulatory Submission for LYNPARZA (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer
Apr 3, 2018 06:00AM The European Medicines Agency Accepts Regulatory Submission for LYNPARZA® (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer
Apr 2, 2018 06:45AM Merck to Hold First-Quarter 2018 Sales and Earnings Conference Call on May 1
Mar 23, 2018 06:25AM Eisai, Merck (MRK) Announce Anticancer Agent LENVIMA was Approved for Additional Indication of HCC in Japan
Mar 23, 2018 06:00AM Anticancer Agent LENVIMA® (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
Mar 21, 2018 06:24AM Merck's (MRK) MSD Animal Health Receives Positive Opinion from EMA for BRAVECTO Plus Spot-on Solution for Cats
Mar 21, 2018 02:00AM MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO® Plus (fluralaner plus moxidectin) Spot-on Solution for Cats
Mar 20, 2018 04:05PM Merck Announces Appointment of Jennifer Zachary as General Counsel
Mar 14, 2018 06:30PM First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting
Mar 13, 2018 07:02AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA for Treatment of Advanced Cervical Cancer
View More Recent Stories View Older Stories